Not checkedNot checked for notices yet.
Síndrome de ativação macrofágica após uso de Leflunomida em paciente com doença de Still do adulto: relato de caso Macrophage activation syndrome following the use of Leflunomide in a patient with adult-onset Still disease: case report
Dario Júnior de Freitas Rosa, Cristianne Medeiros Nogueira, Herval de Lacerda Bonfante and 4 more
Revista Brasileira de Reumatologia · 2007
doi:10.1590/s0482-50042007000300013 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Paciente do sexo feminino, 32 anos de idade, com doença de Still do adulto, após 15 dias da introdução de leflunomida é admitida com quadro de febre persistente e crise convulsiva tônico-clônica generalizada, rapidamente evoluindo com hepatosplenomegalia, distúrbio da função hepática, trombocitopenia, elevação da lactato-desidrogenase, hipertrigliceridemia, hiperferritinemia e insuficiência renal, levando ao diagnóstico de síndrome de ativação macrofágica, uma complicação rara das doenças reumatológicas que resulta de ativação e proliferação incontrolada de linfócitos T e de excessiva ativação de macrófagos. Pode evoluir com coagulação intravascular disseminada, sendo o envolvimento renal raro. A terapêutica deve ser por meio de pulsoterapia com metilpredinisolona e ciclosporina.<br>A 32-year-old white female, with adult-onset Still disease, was admitted following a 15-day course of leflunomide, with persistent fever and a generalized tonic-clonic seizure. She quickly developed liver and spleen enlargement, impairment of liver function, thrombocytopenia, elevation of lactate-dehydrogenase, trylicerides and ferritin, and renal failure, being diagnosed with the macrophage activation syndrome, a rare complication of rheumatic diseases due to activation and uncontrolled proliferation of T lymphocytes and excessive macrophage activation. The syndrome may lead to disseminated intravascular coagulation, renal impairment being a rare event. Pulse therapy with methylprednisolone and cyclosporine are the therapeutic options.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.